Cell Therapies CEO Bev Menner and ACTRIS Executive Director, A/Prof Aloysius Ho, at Cell Therapies’ facility in Melbourne.
Singapore / Melbourne, Australia – February 11, 2026
Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) announced today that it has signed a Memorandum of Understanding (MoU) with Cell Therapies Pty Ltd, Australia’s leading contract development and manufacturing organisation (CDMO) for cell and gene therapies (CGT), to strengthen ACTRIS’s position as a premier CGT manufacturing hub in Asia. This MoU marks the first step in a strategic collaboration aimed at accelerating ACTRIS’s operational readiness and expanding patient access to advanced therapies across Singapore and the wider Asia Pacific region.
This partnership will combine ACTRIS’s state-of-the-art Good Manufacturing Practice (GMP) infrastructure and vision to be a regional centre of excellence with Cell Therapies’ decades of experience in CGT development, clinical translation, and commercial manufacturing. Together, the organisations will work to streamline manufacturing processes, enhance compliance, and build sustainable capabilities for CGT development and commercialisation.
Importantly, this collaboration also reflects Cell Therapies’ continued commitment to strengthening its Asia Pacific Alliance Model (APAM)-a distributed network designed to enable efficient technology transfer, regional manufacturing access, and a single, coordinated pathway for global sponsors seeking to advance CGT programs across APAC.
Key Objectives of the Collaboration
- Optimize GMP-compliant manufacturing processes for CGT
- Enable efficient technology transfer and scale-up capabilities
- Strengthen regulatory strategy and compliance to meet international standards
- Build long-term infrastructure and workforce capability through training and development initiatives
Statements from Company Leaders
ACTRIS A/Prof Aloysius Ho, Executive Director:
“Signing this MoU with Cell Therapies represents a pivotal step in ACTRIS’s journey to be the national and regional centre of excellence for process development and manufacturing of cellular-based therapeutics,” said Aloysius Ho, Executive Director at ACTRIS. “Our collaboration will accelerate readiness for clinical and commercial supply, ensuring patients across the region gain timely access to life-changing therapies.”
Cell Therapies Pty Ltd Bev Menner, CEO:
“We are delighted to partner with ACTRIS to strengthen advanced manufacturing capabilities in Singapore,” said Bev Menner, CEO of Cell Therapies. “This collaboration underscores our shared commitment to building a connected CGT ecosystem across Asia Pacific, enabling streamlined pathways for clinical trials and commercial supply.”
To learn more about ACTRIS, please click here: https://www.actris.sg
To learn more about Cell Therapies, please click here: https://celltherapies.com/
Media Contacts
Cell Therapies Pty Ltd
Name: Dr Shrinidh Joshi, Director of Business Development
Email: [email protected]
Phone: +61 3 9492 4777
For further information please contact [email protected]
